KYMR
HealthcareKymera Therapeutics, Inc. · Biotechnology · $6B
What is Kymera Therapeutics, Inc.?
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation — a novel approach to eliminating disease-causing proteins using the body's own cellular machinery.
Kymera designs small molecule drugs that selectively tag and destroy proteins driving disease, rather than simply blocking them. Its pipeline spans immunology, inflammation, and oncology, with programs targeting conditions such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and hematologic malignancies.
Incorporated in 2015 and headquartered in Watertown, Massachusetts.
- IRAK4 degrader program (immunology and inflammation)
- IRAKIMiD program (B-cell lymphoma)
- STAT3 degrader program (oncology and autoimmune disease)
- MDM2 degrader program (hematological and solid tumors)
Is KYMR a Good Stock to Buy?
UQS Score rates KYMR as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biotech companies.
The Risk pillar stands out as the relative bright spot, suggesting the company's balance sheet provides some runway compared to peers at a similar development stage.
Quality, Moat, and Growth all register as Weak, consistent with a company that has not yet generated commercial revenue. Valuation is rated Elevated, meaning the current price reflects significant future expectations.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does KYMR pay dividends?
No — Kymera Therapeutics, Inc. does not currently pay a dividend.
Kymera does not pay a dividend. As a clinical-stage company, available capital is directed toward research, clinical trials, and pipeline advancement — the standard approach for pre-commercial biotechs where reinvestment is the primary value driver.
When does KYMR report earnings?
Kymera Therapeutics reports financial results on a quarterly cadence, standard for US-listed companies.
As a pre-revenue company, quarterly reports focus primarily on cash position, operating expenses, and clinical program updates rather than sales or profitability metrics. Pipeline milestones tend to drive more market reaction than the financial figures themselves.
For the most current quarterly results and clinical updates, visit Kymera Therapeutics' investor relations page directly.
KYMR Price History
+83.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Kymera Therapeutics, Inc.?
Based on Kymera Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Kymera Therapeutics do?
Kymera develops small molecule drugs that degrade disease-causing proteins by leveraging the body's natural protein disposal system. Its pipeline targets inflammatory diseases such as atopic dermatitis and rheumatoid arthritis, as well as blood cancers and solid tumors.
Does KYMR pay dividends?
No. Kymera does not pay a dividend. The company is pre-commercial and reinvests all available capital into its research and clinical programs, which is typical for early-stage biopharmaceutical companies.
When does KYMR report earnings?
Kymera reports on a quarterly basis. Our data source does not provide specific upcoming dates — check the company's investor relations page for the current reporting schedule.
Is KYMR a good stock to buy?
UQS Score rates KYMR as Poor overall. The Risk pillar offers some reassurance on financial runway, but Weak ratings across Quality, Moat, and Growth reflect the challenges of a pre-revenue pipeline company. The full breakdown is available to Pro members.
Is KYMR overvalued?
The UQS Valuation pillar for KYMR is rated Elevated, indicating the current market price embeds substantial expectations for future clinical and commercial success. This is common in clinical-stage biotech but represents meaningful downside risk if trials disappoint.
What is KYMR's market cap bracket?
Kymera Therapeutics is classified as a mid-cap company within the healthcare sector.
Is KYMR a long-term quality investment?
From a UQS quality-indicator perspective, KYMR currently scores Poor. Long-term potential depends heavily on clinical trial outcomes and eventual commercialization. Investors should weigh the Weak Quality and Moat ratings alongside the company's pipeline progress.
What is the main competitive advantage of Kymera Therapeutics?
Kymera's focus on targeted protein degradation — a relatively novel drug modality — differentiates it from traditional small molecule or antibody-based approaches. However, the UQS Moat pillar is currently rated Weak, reflecting the early and unproven stage of this competitive position.
Unlock Full KYMR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare KYMR side-by-side with clinical-stage biotech peers
- ✓Get the full analyst-style breakdown in one place
Pro Analysis
KYMR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 14.9 | 0.0 | 32.0 | 0.0 | 46.2 | 0.0 | -4.3 |
| May 4, 2026 | 19.2 | 0.8 | 32.0 | 5.0 | 66.7 | 0.0 | -1.9 |
| Apr 2, 2026 | 21.1 | 0.8 | 32.0 | 14.3 | 66.7 | 0.0 | — |
KYMR — Pillar Breakdown
Quality
— 0.8/100 (25%)Kymera Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 3.5/100 (20%)Kymera Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.3/100 (15%)Kymera Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Kymera Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 32/100 (25%)Kymera Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KYMR.
Score Composition
Financial Data
More Stock Analysis
How is the KYMR UQS Score Calculated?
The UQS (Unified Quality Score) for Kymera Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Kymera Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Kymera Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.